

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for September 2024

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Altius Healthcare Inc.	Cléo-35	Diane-35	CYPROTERONE ACETATE & ETHINYL ESTRADIOL	2 mg & 0.035 mg	tablet	02436736
Marcan Pharmaceuticals Inc.	Mar-Eszopiclone	Lunesta	ESZOPICLONE	1 mg	tablet	02549433
Marcan Pharmaceuticals Inc.	Mar-Eszopiclone	Lunesta	ESZOPICLONE	2 mg	tablet	02549441
Marcan Pharmaceuticals Inc.	Mar-Eszopiclone	Lunesta	ESZOPICLONE	3 mg	tablet	02549468
Teva Canada Limited	Teva-Mirtazapine	REMERON	MIRTAZAPINE	15 mg	tablet	02541572

Teva Canada Limited	Teva-Mirtazapine	REMERON	MIRTAZAPINE	45 mg	tablet	02541580
Sivem Pharmaceuticals	Tadalafil	Cialis	TADALAFIL	2.5 mg	tablet	02536676
Sivem Pharmaceuticals	Tadalafil	Cialis	TADALAFIL	5 mg	tablet	02536684
Sivem Pharmaceuticals	Tadalafil	Cialis	TADALAFIL	10 mg	tablet	02536692
Sivem Pharmaceuticals	Tadalafil	Cialis	TADALAFIL	20 mg	tablet	02536706